The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma

Monoclonal antibodies (mAbs) directed against type 2 (T2) inflammatory pathway have revolutionized the treatment of severe eosinophilic asthma (SEA) by improving symptom control and exacerbation frequency, and reducing exposure to oral corticosteroids (OCSs).1,2 Mepolizumab1 and benralizumab2 target IL-5 and IL-5 receptor-alpha (IL-5R), respectively, inhibiting the eosinophilic inflammatory cascades that underpin the pathogenesis of poor symptom control and exacerbation development in SEA.